Aleksandr Vinogradov, DPM
Foot & Ankle Surgery · Newport, TNNPI 1457914350
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (56.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Arthrex at 45.1% of the total. Reporting peaked in 2022 at $6,202 and has fallen 98.8% since, to $74 in 2025.
Across 58 payments — averaging $159.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$4K
- Mid-atlantic Surgical Systems, LLC$3K
- Smoky Mountain Surgical LLC$1K
- Smith+Nephew$378
- Novo Nordisk$208
- Trimed, Inc.$75
- plus $321 from 11 others
What the payments were for
- Grants$1,16313%
- Travel & lodging$1,45816%
- Food & beverage$1,37015%
- Education$5,23657%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 12 | $4,163 |
| Mid-atlantic Surgical Systems, LLC | 5 | $2,858 |
| Smoky Mountain Surgical LLC | 4 | $1,224 |
| Smith+Nephew | 7 | $378 |
| Novo Nordisk | 11 | $208 |
| Trimed, Inc. | 1 | $75 |
| Johnson & Johnson | 4 | $57 |
| Alpha Orthopedic Systems | 1 | $56 |
| Axsome Therapeutics, Inc. | 3 | $44 |
| Convatec Inc. | 2 | $38 |
| Alkermes, Inc. | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Pfizer | 1 | $14 |
| Organogenesis Inc. | 1 | $13 |
| Integra Lifesciences Corporation | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Stravix$104
How this compares
$9,227 in reported general payments places this provider in the 75th percentile of 145 foot & ankle surgery providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 29 | $1,529 |
| Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort | 25 | $1,388 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 91 | $1,351 |
| Diclofenac Sodium | 21 | $939 |
| Ciclopirox | 27 | $881 |
| Doxycycline Hyclate | 65 | $720 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 23 | $427 |
| Methylprednisolone | 38 | $270 |
| Meloxicam | 80 | $209 |
| Oxycodone Hcl | 75 | $171 |
| Mupirocin | 17 | $143 |
| Terbinafine Hcl | 11 | $127 |
| Cephalexin | 15 | $110 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $82 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Newport
- Sebastien DemoinyMorristown$210K
- Robert ThompsonMurfreesboro$205K
- Bhekumuzi KhumaloUnion City$201K
- Walter ButlerMemphis$191K
- Chad WebsterCordova$185K
- Christian SmithCordova$153K
- Frank OgnibeneMemphis$148K
- Garnett MurphyGermantown$130K
- Clayton BettinMemphis$89K
- David RichardsonGermantown$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.